Renaissance Capital logo

CLLS News

Cream of the gene-edited crop: Calyxt sets terms for $100 million IPO

Cellectis logo

Calyxt, a developer of gene-edited crop traits spun out of Cellectis, announced terms for its IPO on Monday. The New Brighton, MN-based company plans to raise $100 million by offering 6.06 million shares at a price range of $15 to $18. Parent Cellectis may...read more

Survival of the fittest biotechs: Galapagos sets terms for $160 million US IPO

Cellectis logo

Galapagos, a Belgian biotech developing new treatments for inflammatory diseases, announced terms for its IPO on Tuesday. The Mechelen, Belgium-based company plans to raise $160 million by offering 3.78 million ADSs. Its shares are currently listed on...read more

US IPO Weekly Recap: SolarEdge shines while other IPOs fall flat

SEDG

Four companies publicly listed on US markets during the last full week of the first quarter, raising $510 million. Solar tech provider SolarEdge outshined its peers while mega biotech Cellectis saw speculators jump in before the IPO and then quickly jump...read more

Cellectis prices upsized IPO at $41.50, selling 750k additional ADSs over upwardly revised deal size

Cellectis logo

Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T cells, raised $229 million in an upsized IPO by offering 5.5 million ADSs (all primary) at $41.50. The Paris, France-based company had planned to offer 4.8 million ADSs, upwardly...read more